Pfizer Inc. (NYSE: NYSE:) has received conditional marketing authorization from the European Commission for its gene therapy product DURVEQTIX, designed...
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Big investors are positioning themselves for “a turning of the tide” for London’s unloved stock market, hoping that an improving economy, lower interest rates and political stability will finally boost cheap British shares.International asset managers including BlackRock and Allianz have joined UK fund houses such as Ruffer and Rathbones in raising their exposure to UK-listed stocks in recent months.After years of disappointing performance compared with European and US markets, investors now see...